Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTALXS1617

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:41:02 ON 10 APR 2008

```
=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 16:41:40 ON 10 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    9 APR 2008  HIGHEST RN 1013298-21-9
DICTIONARY FILE UPDATES:   9 APR 2008  HIGHEST RN 1013298-21-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s coumaryl quinic acid
            74 COUMARYL
           125 QUINIC
       9355238 ACID
          8239 ACIDS
       9361176 ACID
                   (ACID OR ACIDS)
L1            2 COUMARYL QUINIC ACID
                   (COUMARYL(W)QUINIC(W)ACID)

=> d l1

L1   ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   928012-37-7  REGISTRY
ED   Entered STN:  23 Mar 2007
CN   Cyclohexanecarboxylic acid, 3,4,5-trihydroxy-1-[[(2E)-3-(4-hydroxyphenyl)-
     1-oxo-2-propen-1-yl]oxy]-, (1α,3R,4α,5R)-  (CA INDEX NAME)
OTHER NAMES:
CN   1-O-p-Coumaroylquinic acid
CN   1-p-Coumarylquinic acid
FS   STEREOSEARCH
DR   53505-94-5
MF   C16 H18 O8
SR   CA
LC   STN Files:   BEILSTEIN*, CA, CAPLUS
         (*File contains numerically searchable property data)

Absolute stereochemistry.
Double bond geometry as shown.
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d l1 2

L1 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2008 ACS on STN
RN 1899-30-5 REGISTRY
ED Entered STN: 16 Nov 1984
CN Cyclohexanecarboxylic acid, 1,3,4-trihydroxy-5-[[3-(4-hydroxyphenyl)-1-oxo-2-propen-1-yl]oxy]-, (1S,3R,4R,5R)- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cinnamic acid, p-hydroxy-, 3-ester with 1,3,4,5-tetrahydroxycyclohexanecarboxylic acid (7CI, 8CI)
CN Cyclohexanecarboxylic acid, 1,3,4-trihydroxy-5-[[3-(4-hydroxyphenyl)-1-oxo-2-propenyl]oxy]-, (1S,3R,4R,5R)- (9CI)
CN Cyclohexanecarboxylic acid, 1,3,4-trihydroxy-5-[[3-(4-hydroxyphenyl)-1-oxo-2-propenyl]oxy]-, [1S-(1α,3α,4α,5β)]-
OTHER NAMES:
CN 3-O-p-Coumaroylquinic acid
CN 3-O-p-Coumarylquinic acid
CN 3-p-Coumaroylquinic acid
CN 3-p-Coumarylquinic acid
FS STEREOSEARCH
DR 19030-00-3, 19030-11-6
MF C16 H18 O8
LC STN Files: AGRICOLA, BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, NAPRALERT, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.
Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

181 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
181 REFERENCES IN FILE CAPLUS (1907 TO DATE)
20 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s 1899-30-5 /rn
L2 1 1899-30-5 /RN

=> file medicine
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 21.75 21.96

FILE 'ADISCTI' ENTERED AT 16:44:37 ON 10 APR 2008
COPYRIGHT (C) 2008 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 16:44:37 ON 10 APR 2008
COPYRIGHT (C) 2008 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 16:44:37 ON 10 APR 2008
COPYRIGHT (C) 2008 Adis Data Information BV

FILE 'BIOSIS' ENTERED AT 16:44:37 ON 10 APR 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'BIOTECHNO' ENTERED AT 16:44:37 ON 10 APR 2008
COPYRIGHT (C) 2008 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CAPLUS' ENTERED AT 16:44:37 ON 10 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DDFB' ENTERED AT 16:44:37 ON 10 APR 2008
COPYRIGHT (C) 2008 THE THOMSON CORPORATION

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 16:44:37 ON 10 APR 2008
COPYRIGHT (C) 2008 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 16:44:37 ON 10 APR 2008
COPYRIGHT (C) 2008 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DRUGB' ENTERED AT 16:44:37 ON 10 APR 2008
COPYRIGHT (C) 2008 THE THOMSON CORPORATION

FILE 'DRUGMONOG2' ENTERED AT 16:44:37 ON 10 APR 2008
COPYRIGHT (C) 2008 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 16:44:37 ON 10 APR 2008
COPYRIGHT (C) 2008 THE THOMSON CORPORATION

FILE 'EMBAL' ENTERED AT 16:44:37 ON 10 APR 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'EMBASE' ENTERED AT 16:44:37 ON 10 APR 2008

FILE 'ESBIOBASE' ENTERED AT 16:44:37 ON 10 APR 2008

FILE 'IFIPAT' ENTERED AT 16:44:37 ON 10 APR 2008

FILE 'IMSDRUGNEWS' ENTERED AT 16:44:37 ON 10 APR 2008

FILE 'IMSPRODUCT' ENTERED AT 16:44:37 ON 10 APR 2008

FILE 'IPA' ENTERED AT 16:44:37 ON 10 APR 2008

FILE 'KOSMET' ENTERED AT 16:44:37 ON 10 APR 2008

FILE 'LIFESCI' ENTERED AT 16:44:37 ON 10 APR 2008

FILE 'MEDLINE' ENTERED AT 16:44:37 ON 10 APR 2008

FILE 'NAPRALERT' ENTERED AT 16:44:37 ON 10 APR 2008

FILE 'NLDB' ENTERED AT 16:44:37 ON 10 APR 2008

FILE 'NUTRACEUT' ENTERED AT 16:44:37 ON 10 APR 2008

FILE 'PASCAL' ENTERED AT 16:44:37 ON 10 APR 2008

FILE 'PCTGEN' ENTERED AT 16:44:37 ON 10 APR 2008

FILE 'PHARMAML' ENTERED AT 16:44:37 ON 10 APR 2008

FILE 'PHIC' ENTERED AT 16:44:37 ON 10 APR 2008

FILE 'PHIN' ENTERED AT 16:44:37 ON 10 APR 2008

FILE 'SCISEARCH' ENTERED AT 16:44:37 ON 10 APR 2008

FILE 'TOXCENTER' ENTERED AT 16:44:37 ON 10 APR 2008

FILE 'USGENE' ENTERED AT 16:44:37 ON 10 APR 2008

FILE 'USPATFULL' ENTERED AT 16:44:37 ON 10 APR 2008

FILE 'USPATOLD' ENTERED AT 16:44:37 ON 10 APR 2008

FILE 'USPAT2' ENTERED AT 16:44:37 ON 10 APR 2008


```
=> s l2
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
L3         244 L2

=> s l3 and leukemia
L4          15 L3 AND LEUKEMIA

=> dup rem l4
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGMONOG2,
IMSPRODUCT, KOSMET, NUTRACEUT, PCTGEN, PHARMAML, USGENE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L4
L5           11 DUP REM L4 (4 DUPLICATES REMOVED)

=> d l5 bib abs 1-11

L5   ANSWER 1 OF 11  USPATFULL on STN
AN     2007:210325  USPATFULL
TI     Herbal composition for treating CD33+ acute and chronic myeloid
       leukemia and a method thereof
IN     Bandyopadhyay, Santu, Calcutta, INDIA
       Roy, Keshab Chandra, Calcutta, INDIA
       Ray, Mitali, Calcutta, INDIA
       Banerjee, Goutam, Calcutta, INDIA
       Pal, Bikash Chandra, Calcutta, INDIA
       Biswas, Tanusree, Calcutta, INDIA
       Bhattacharya, Samir, Calcutta, INDIA
PA     COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH, NEW DELHI, INDIA
       (non-U.S. corporation)
PI     US 2007184131       A1  20070809
AI     US 2007-730433      A1  20070402 (11)
RLI    Division of Ser. No. US 2004-960064, filed on 8 Oct 2004, PENDING
       Division of Ser. No. US 2002-207039, filed on 30 Jul 2002, GRANTED, Pat.
       No. US 6852344 Continuation-in-part of Ser. No. US 2001-772003, filed on
       30 Jan 2001, ABANDONED
PRAI   WO 2000-IN118       20001204
```

US 2002-384163P 20020531 (60)
DT Utility
FS APPLICATION
LREP FITZPATRICK CELLA HARPER & SCINTO, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112, US
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 914
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of treating CD33+ acute and chronic myeloid leukemia in animals including humans, using fraction nos. 1 and 9 obtained from water:methanol fraction by column chromatography, with ratio of water and methanol ranging between 1:5 to 5:1, wherein said water:methanol fraction is obtained from the polar extract of Piper betel by HPLC, with retention time of 3.6 and 24.0 minutes respectively, with said fractions used both individually, and in combination.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 11 USPATFULL on STN
AN 2007:184711 USPATFULL
TI Pharmaceutical composition useful for treating chronic myeloid leukemia
IN Bandyopadhyay, Santu, Kolkata, INDIA
Pal, Bikas Chandra, Kolkata, INDIA
Bhattacharyay, Samir, Kolkata, INDIA
Mondal, Swapan, Kolkata, INDIA
Mandal, Chhabinath, Kolkata, INDIA
Konar, Aditya, Kolkata, INDIA
Roy, Keshab Chandra, Kolkata, INDIA
Biswas, Tanusree, Kolkata, INDIA
Bandyopadhyay, Gautam, Kolkata, INDIA
PA COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH, NEW DELHI, INDIA (non-U.S. corporation)
PI US 2007161704 A1 20070712
AI US 2006-640401 A1 20061218 (11)
RLI Continuation of Ser. No. US 2005-174545, filed on 6 Jul 2005, ABANDONED Continuation-in-part of Ser. No. US 2003-338689, filed on 9 Jan 2003, ABANDONED
PRAI US 2002-393750P 20020708 (60)
DT Utility
FS APPLICATION
LREP FITZPATRICK CELLA HARPER & SCINTO, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112, US
CLMN Number of Claims: 24
ECL Exemplary Claim: 1-44
DRWN 10 Drawing Page(s)
LN.CNT 817
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to a pharmaceutical composition useful for treating chronic myeloid leukemia where Bcr-Abl kinase is constitutively expressed in animals and humans, and a treatment of chronic myeloid leukemia (CML) by a composition comprising an effective amount of analogs and/or salts of chlorogenic acid. The analogs are preferably sodium chlorogenate (Na-Chl) or potassium or ammonium salts, which were prepared from Chlorogenic acid or its analogs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 11 USPATFULL on STN DUPLICATE 1

AN 2005:104652 USPATFULL
TI Herbal composition for treating CD33and chronic myeloid leukemia and a method thereof
IN Bandyopadhyay, Santu, Calcutta, INDIA
Roy, Keshab Chandra, Calcutta, INDIA
Ray, Mitali, Calcutta, INDIA
Banerjee, Goutam, Calcutta, INDIA
Pal, Bikash Chandra, Calcutta, INDIA
Biswas, Tanusree, Calcutta, INDIA
Bhattacharya, Samir, Calcutta, INDIA
PA COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH, NEW DELHI, INDIA (non-U.S. corporation)
PI US 2005089585 A1 20050428
US 7306817 B2 20071211
AI US 2004-960064 A1 20041008 (10)
RLI Division of Ser. No. US 2002-207039, filed on 30 Jul 2002, GRANTED, Pat. No. US 6852344 Continuation-in-part of Ser. No. US 2001-772003, filed on 30 Jan 2001, ABANDONED
PRAI WO 2000-IN118 20001204
US 2002-384163P 20020531 (60)
DT Utility
FS APPLICATION
LREP FITZPATRICK CELLA HARPER & SCINTO, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112, US
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 976
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method of treating CD33+ acute and chronic myeloid leukemia in animals including humans, using fraction nos. 1 and 9 obtained from water:methanol fraction by column chromatography, with ratio of water and methanol ranging between 1:5 to 5:1, wherein said water:methanol fraction is obtained from the polar extract of piper betel by HPLC, with retention time of 3.6 and 24.0 minutes respectively, with said fractions used both individually, and in combination, and a composition comprising the said fraction nos. 1 and 9.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 11 USPATFULL on STN DUPLICATE 2
AN 2004:57084 USPATFULL
TI Herbal based composition for treating acute and chronic myeloid leukemia
IN Bandyopadhyay, Santu, Calcutta, INDIA
Roy, Keshab Chandra, Calcutta, INDIA
Ray, Mitali, Kolkata, INDIA
Bandyopadhyay, Gautam, Kolkata, INDIA
Pal, Bikash Chandra, Kolkata, INDIA
Biswas, Tanusree, Kolkata, INDIA
Bhattacharya, Samir, Kolkata, INDIA
PI US 2004043086 A1 20040304
US 6967034 B2 20051122
AI US 2003-448398 A1 20030530 (10)
PRAI US 2002-384163P 20020531 (60)
DT Utility
FS APPLICATION
LREP FITZPATRICK CELLA HARPER & SCINTO, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112
CLMN Number of Claims: 21
ECL Exemplary Claim: 1

DRWN 7 Drawing Page(s)
LN.CNT 460
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A new herbal-based composition and method for treatment of CD33+ acute and chronic myeloid leukemia by Piper betel leaf extracts, and to provide a process for the isolation of active fractions from leaves or any other plant parts of Piper betel to treat CD3 3+ AML and CML with a simplified method of isolation of active components from all plant parts of Piper betel possessing biological activities relevant to the treatment of CD33+ AML and CML.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:1160293 CAPLUS
DN 145:443788
TI A method of isolating fraction from aerial parts of Piper betel
IN Bandyopadhyay, Santu; Pal, Bikas Chandra; Bhattacharya, Samir; Biswas, Tanusree; Ray, Mitali; Roy, Keshab Chandra; Bandyopadhyay, Gautam
PA Council of Scientific and Industrial Research, India
SO Indian, 21 pp.
CODEN: INXXAP
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI IN 195001	A1	20041218	IN 2003-DE755	20030530
PRAI IN 2003-DE755		20030530		

AB This invention relates to a method of isolating fraction from aerial parts of Piper betel for treatment of CD33+ acute and chronic myeloid leukemia. Isolation of fractions have been carried out using polar water soluble solvents. Fractions of Piper betel leaf exts. are also purified by chromatog. methods to obtain 3-O-p-coumarylquinic acid.

L5 ANSWER 6 OF 11 USPATFULL on STN
AN 2004:69647 USPATFULL
TI Synergistic composition for treating leukemia
IN Bandyopadhyay, Santu, Kolkata, INDIA
Chandra Pal, Bikash, Kolkata, INDIA
Bhattacharya, Samir, Kolkata, INDIA
Roy, Keshab Chandra, Kolkata, INDIA
Bandyopadhyay, Gautam, Kolkata, INDIA
PA Council Of Scientific & Industrial Research, New Delhi, INDIA, 110 001 (non-U.S. corporation)
PI US 2004052874 A1 20040318
AI US 2003-613122 A1 20030707 (10)
PRAI US 2002-393750P 20020708 (60)
DT Utility
FS APPLICATION
LREP FITZPATRICK CELLA HARPER & SCINTO, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 685
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a method of treating acute and chronic myeloid leukemia (AML & CML) and lymphoid leukemia, said method comprising administering a pharmaceutical composition comprising pharmaceutically effective amount of chlorogenic acid (CA) and 3-o-p-Coumaryl quinic acid (PCQ) isolated from any plant parts of

Piper betel or any other source, both individually or in a synergistic combination optionally along with pharmaceutically acceptable additives.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 11 USPATFULL on STN
AN 2004:7898 USPATFULL
TI Pharmaceutical composition useful for treating chronic myeloid leukemia
IN Bandyopadhyay, Santu, Kolkata, INDIA
Pal, Bikas Chandra, Kolkata, INDIA
Bhattacharyay, Samir, Kolkata, INDIA
Mondal, Swapan, Calcutta, INDIA
Mandal, Chhabinath, Calcutta, INDIA
Konar, Aditya, Calcutta, INDIA
Roy, Keshab Chandra, Calcutta, INDIA
Biswas, Tanusree, Calcutta, INDIA
Bandyopadhyay, Gautam, Calcutta, INDIA
PA COUNCIL OF SCIENTIFIC (non-U.S. corporation)
INDUSTRIAL RESEARCH (non-U.S. corporation)
PI US 2004006138 A1 20040108
AI US 2003-338689 A1 20030109 (10)
PRAI US 2002-393750P 20020708 (60)
DT Utility
FS APPLICATION
LREP FITZPATRICK CELLA HARPER & SCINTO, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 591
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a pharmaceutical composition useful for treating chronic myeloid leukemia where Bcr-Abl kinase is constitutively expressed in animals and humans, said composition comprising an effective amount of analogs of chlorogenic acid such as neochlorogenic acid (5-O-caffeoyl quinic acid), cryptochlorogenic acid (4-O-Caffeoyl quinic acid), 3-O-(3'-methylcaffeoyl) quinic acid and 5-O-(Caffeoyl-4'-methyl) quinic acid and/or its salts such as sodium, potassium and ammonium together with pharmaceutically acceptable additives.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 3
AN 2003:971883 CAPLUS
DN 140:13037
TI A herbal molecule as potential anti-leukemic drug
IN Bandyopadhyay, Santu; Pal, Bikash Chandra; Battacharya, Samir; Roy, Keshab Chandra; Bandyopadhyay, Gautam
PA Council of Scientific and Industrial Research, India
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003101446	A1	20031211	WO 2002-IB5565	20021220
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA	2488287	A1	20031211	CA 2002-2488287	20021220
AU	2002348746	A1	20031219	AU 2002-348746	20021220
EP	1511475	A1	20050309	EP 2002-781696	20021220
EP	1511475	B1	20051005		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

CN	1646112	A	20050727	CN 2002-829404	20021220
JP	2005531593	T	20051020	JP 2004-508804	20021220
RU	2314096	C2	20080110	RU 2004-135078	20021220
US	20030229140	A1	20031211	US 2003-338688	20030109
CA	2492278	A1	20040115	CA 2003-2492278	20030110
WO	2004004708	A1	20040115	WO 2003-IB44	20030110
WO	2004004708	A9	20060504		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2003201062	A1	20040123	AU 2003-201062	20030110
EP	1524973	A1	20050427	EP 2003-762826	20030110

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

CN	1678300	A	20051005	CN 2003-820559	20030110
JP	2006519752	T	20060831	JP 2004-519034	20030110
US	20040043086	A1	20040304	US 2003-448398	20030530
US	6967034	B2	20051122		
US	20040052874	A1	20040318	US 2003-613122	20030707
IN	2003DE01280	A	20050311	IN 2003-DE1280	20031016
IN	2004DN02396	A	20070406	IN 2004-DN2396	20040817

PRAI US 2002-384163P P 20020531
US 2002-393750P P 20020708
WO 2002-IB5565 W 20021220
US 2003-338688 A 20030109
WO 2003-IB44 W 20030110
IN 2003-DN643 A3 20030428
US 2003-613122 A 20030707

AB The present invention relates to a new use of the compound chlorogenic acid isolated from the piper betel leaf extract or from any other sources for the treatment of acute and chronic myeloid leukemia and lymphoid leukemia, and the present invention also provides a pharmaceutical composition comprising chlorogenic acid along with pharmaceutically acceptable additive for the treatment of acute and chronic myeloid leukemia and lymphoid leukemia.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 11 USPATFULL on STN DUPLICATE 4
AN 2003:71049 USPATFULL
TI Herbal composition for treating CD33+ acute and chronic myeloid leukemia and a method thereof

IN Bandyopadhyay, Santu, Calcutta, INDIA
Roy, Keshab Chandra, Calcutta, INDIA
Ray, Mitali, Calcutta, INDIA
Banerjee, Goutam, Calcutta, INDIA
Pal, Bikash Chandra, Calcutta, INDIA
Biswas, Tanusree, Calcutta, INDIA
Bhattacharya, Samir, Calcutta, INDIA
PA COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (non-U.S. corporation)
PI US 2003049334 A1 20030313
US 6852344 B2 20050208
AI US 2002-207039 A1 20020730 (10)
RLI Continuation-in-part of Ser. No. US 2001-772003, filed on 30 Jan 2001, ABANDONED
PRAI WO 2000-IN118 20001204
US 2002-384163P 20020531 (60)
DT Utility
FS APPLICATION
LREP FITZPATRICK CELLA HARPER & SCINTO, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112
CLMN Number of Claims: 46
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 1041
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method of treating CD33+ acute and chronic myeloid leukemia in animals including humans, using fraction nos. 1 and 9 obtained from water:methanol fraction by column chromatography, with ratio of water and methanol ranging between 1:5 to 5:1, wherein said water:methanol fraction is obtained from the polar extract of piper betel by HPLC, with retention time of 3.6 and 24.0 minutes respectively, with said fractions used both individually, and in combination, and a composition comprising the said fraction nos. 1 and 9.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 11 USPATFULL on STN
AN 2003:325158 USPATFULL
TI Herbal molecule as potential anti-leukemic drug
IN Bandyopadhyay, Santu, Calcutta, INDIA
Pal, Bikash Chandra, Kolkata, INDIA
Bhattacharya, Samir, Kolkata, INDIA
Roy, Keshab Chandra, Kolkata, INDIA
Bandyopadhyay, Gautam, Kolkata, INDIA
PI US 2003229140 A1 20031211
AI US 2003-338688 A1 20030109 (10)
PRAI WO 2002-IB5565 20021220
US 2002-384163P 20020531 (60)
US 2002-393750P 20020708 (60)
DT Utility
FS APPLICATION
LREP FITZPATRICK CELLA HARPER & SCINTO, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112
CLMN Number of Claims: 49
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 676
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a new use of the compound chlorogenic acid isolated from the piper betel leaf extract or from any other sources for the treatment of acute and chronic myeloid leukemia and lymphoid leukemia, and the present invention also provides

```
       a pharmaceutical composition comprising chloregenic acid along with
       pharmaceutically acceptable additive for the treatment of acute and
       chronic myeloid leukemia and lymphoid leukemia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5   ANSWER 11 OF 11  USPATFULL on STN
AN       2002:133246  USPATFULL
TI       Antimonocytic activity of betel leaf extracts
IN       Bandyopadhyay, Santu, Calcutta, INDIA
         Pal, Bikash, Calcutta, INDIA
         Bhattacharya, Samir, Calcutta, INDIA
         Ray, Mitali, Calcutta, INDIA
         Roy, Keshab Chandra, Calcutta, INDIA
PI       US 2002068096       A1  20020606
AI       US 2001-772003      A1  20010130 (9)
PRAI     WO 2000-IN118       20001204
DT       Utility
FS       APPLICATION
LREP     FITZPATRICK CELLA HARPER & SCINTO, 30 ROCKEFELLER PLAZA, NEW YORK, NY,
         10112
CLMN     Number of Claims: 39
ECL      Exemplary Claim: 1
DRWN     1 Drawing Page(s)
LN.CNT 364
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB       This invention relates to anti-monocytic activity of betel leaf extracts
         and this anti monocytic activity of betel leaf extracts suggest its use
         to treat myeloid leukemia in animal and human beings.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> s 928012-37-7/rn
'RN' IS NOT A VALID FIELD CODE
NUMERIC VALUE NOT VALID '928012-37-7'
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
```

'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
L6 3 928012-37-7/RN

=> dup rem l6
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGMONOG2, IMSPRODUCT, KOSMET, NUTRACEUT, PCTGEN, PHARMAML, USGENE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L6
L7 3 DUP REM L6 (0 DUPLICATES REMOVED)

=> s l7 and leukemia
L8 0 L7 AND LEUKEMIA

=> d l7 bib abs 1-3

L7 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:16930 CAPLUS
DN 146:301878
TI Profiling the Chlorogenic Acids and Other Caffeic Acid Derivatives of Herbal Chrysanthemum by LC-MSn
AU Clifford, Michael N.; Wu, Weiguo; Kirkpatrick, Jo; Kuhnert, Nikolai
CS School of Biomedical and Molecular Sciences, Centre for Nutrition and Food Safety, University of Surrey, Guildford, Surrey, GU2 7XH, UK
SO Journal of Agricultural and Food Chemistry (2007), 55(3), 929-936
CODEN: JAFCAU; ISSN: 0021-8561
PB American Chemical Society
DT Journal
LA English
AB Four samples of herbal chrysanthemum were profiled qual. by LC-MS5 to identify their component chlorogenic acids and partially characterize other caffeic acid derivs. The chlorogenic acids were minor components, and the 4 samples varied markedly in profile. Three p-coumaroylquinic acids, 3 feruloylquinic acids, 4 caffeoylquinic acids, 6 dicaffeoylquinic acids, and 2 tricaffeoylquinic acids were detected, 13 for the first time from this source. Partial characterization of minor components suggested the presence of five caffeoyl-hexose esters and caffeic acid-4-β-D-glucose that have not previously been reported from this source, and eight caffeoylquinic acid glycosides and 16 dicaffeoylquinic acid glycosides that have not previously been reported in nature. Succinic acid-containing chlorogenic acids and chlorogenic acids based on epi-quinic acid, previously reported in Chrysanthemum spp., were not detected in these samples.
RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:1081081 CAPLUS
DN 146:415997
TI Genome-wide analysis of the structural genes regulating defense phenylpropanoid metabolism in Populus
AU Tsai, Chung-Jui; Harding, Scott A.; Tschaplinski, Timothy J.; Lindroth, Richard L.; Yuan, Yinan
CS Biotechnology Research Center, School of Forest Resources and Environmental Science, Michigan Technological University, Houghton, MI, 49931, USA
SO New Phytologist (2006), 172(1), 47-62
CODEN: NEPHAV; ISSN: 0028-646X
PB Blackwell Publishing Ltd.
DT Journal
LA English

AB Salicin-based phenolic glycosides, hydroxycinnamate derivs. and flavonoid-derived condensed tannins comprise up to one-third of Populus leaf dry mass. Genes regulating the abundance and chemical diversity of these substances have not been comprehensively analyzed in tree species exhibiting this metabolically demanding level of phenolic metabolism Here, shikimate-phenylpropanoid pathway genes thought to give rise to these phenolic products were annotated from the Populus genome, their expression assessed by semiquant. or quant. reverse transcription polymerase chain reaction (PCR), and metabolic evidence for function presented. Unlike Arabidopsis, Populus leaves accumulate an array of hydroxycinnamoyl-quinate esters, which is consistent with broadened function of the expanded hydroxycinnamoyl-CoA transferase gene family. Greater flavonoid pathway diversity is also represented, and flavonoid gene families are larger. Consistent with expanded pathway function, most of these genes were upregulated during wound-stimulated condensed tannin synthesis in leaves. The suite of Populus genes regulating phenylpropanoid product accumulation should have important application in managing phenolic carbon pools in relation to climate change and global carbon cycling.
RE.CNT 86 THERE ARE 86 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1974:576186 CAPLUS
DN 81:176186
OREF 81:27167a,27170a
TI Polarimetric analysis of hydroxycinnamic acid esters
AU Dranik, L. I.; Litvinenko, V. I.
CS Khar'k. Nauchno-Issled. Khim.-Farm. Inst., Kharkov, USSR
SO Fenol'nye Soedin. Ikh Fiziol. Svoistva, Mater. Vses. Simp. Fenol'nym Soedin., 2nd (1973), Meeting Date 1971, 176-80. Editor(s): Klyshev, L. K. Publisher: "Nauka" Kaz. SSR, Alma-Ata, USSR.
CODEN: 28MHAX
DT Conference
LA Russian
AB Polarimetric measurements of the following esters of quinic acid were performed: 1-caffeyl, 1-feruloyl, 1-(p-coumaroyl), 1-galloyl, 5-caffeyl, 5-(p-coumaroyl), 5-galloyl, 3-pheruloyl, 3-(p-coumaroyl), 3-galloyl, 4-caffeyl, 4-(p-coumaroy), 4-galloyl, 4,5-dicafferyl, 1,5-dicaffeyl, 1,4-dicaffeyl, and 4,5-digalloyl. For measurements the substances were dissolved in either H2O, MeOH, or Me2CO. Conformations of the esters measured were suggested.

=> s l3 and cancer
8 FILES SEARCHED...
L9 18 L3 AND CANCER

=> dup rem l9
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGMONOG2, IMSPRODUCT, KOSMET, NUTRACEUT, PCTGEN, PHARMAML, USGENE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L9
L10 12 DUP REM L9 (6 DUPLICATES REMOVED)

=> d l10 1-12 bib abs

L10 ANSWER 1 OF 12 USPATFULL on STN
AN 2007:210325 USPATFULL
TI Herbal composition for treating CD33+ acute and chronic myeloid leukemia and a method thereof
IN Bandyopadhyay, Santu, Calcutta, INDIA
Roy, Keshab Chandra, Calcutta, INDIA

Ray, Mitali, Calcutta, INDIA
Banerjee, Goutam, Calcutta, INDIA
Pal, Bikash Chandra, Calcutta, INDIA
Biswas, Tanusree, Calcutta, INDIA
Bhattacharya, Samir, Calcutta, INDIA
PA COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH, NEW DELHI, INDIA (non-U.S. corporation)
PI US 2007184131 A1 20070809
AI US 2007-730433 A1 20070402 (11)
RLI Division of Ser. No. US 2004-960064, filed on 8 Oct 2004, PENDING Division of Ser. No. US 2002-207039, filed on 30 Jul 2002, GRANTED, Pat. No. US 6852344 Continuation-in-part of Ser. No. US 2001-772003, filed on 30 Jan 2001, ABANDONED
PRAI WO 2000-IN118 20001204
US 2002-384163P 20020531 (60)
DT Utility
FS APPLICATION
LREP FITZPATRICK CELLA HARPER & SCINTO, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112, US
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 914
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of treating CD33+ acute and chronic myeloid leukemia in animals including humans, using fraction nos. 1 and 9 obtained from water:methanol fraction by column chromatography, with ratio of water and methanol ranging between 1:5 to 5:1, wherein said water:methanol fraction is obtained from the polar extract of Piper betel by HPLC, with retention time of 3.6 and 24.0 minutes respectively, with said fractions used both individually, and in combination.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 2 OF 12 USPATFULL on STN
AN 2007:184711 USPATFULL
TI Pharmaceutical composition useful for treating chronic myeloid leukemia
IN Bandyopadhyay, Santu, Kolkata, INDIA
Pal, Bikas Chandra, Kolkata, INDIA
Bhattacharyay, Samir, Kolkata, INDIA
Mondal, Swapan, Kolkata, INDIA
Mandal, Chhabinath, Kolkata, INDIA
Konar, Aditya, Kolkata, INDIA
Roy, Keshab Chandra, Kolkata, INDIA
Biswas, Tanusree, Kolkata, INDIA
Bandyopadhyay, Gautam, Kolkata, INDIA
PA COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH, NEW DELHI, INDIA (non-U.S. corporation)
PI US 2007161704 A1 20070712
AI US 2006-640401 A1 20061218 (11)
RLI Continuation of Ser. No. US 2005-174545, filed on 6 Jul 2005, ABANDONED Continuation-in-part of Ser. No. US 2003-338689, filed on 9 Jan 2003, ABANDONED
PRAI US 2002-393750P 20020708 (60)
DT Utility
FS APPLICATION
LREP FITZPATRICK CELLA HARPER & SCINTO, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112, US
CLMN Number of Claims: 24
ECL Exemplary Claim: 1-44
DRWN 10 Drawing Page(s)
LN.CNT 817

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to a pharmaceutical composition useful for treating chronic myeloid leukemia where Bcr-Abl kinase is constitutively expressed in animals and humans, and a treatment of chronic myeloid leukemia (CML) by a composition comprising an effective amount of analogs and/or salts of chlorogenic acid. The analogs are preferably sodium chlorogenate (Na-Chl) or potassium or ammonium salts, which were prepared from Chlorogenic acid or its analogs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 1
AN 2007:1372987 CAPLUS
DN 148:190778
TI Polyphenols Are Intensively Metabolized in the Human Gastrointestinal Tract after Apple Juice Consumption
AU Kahle, Kathrin; Huemmer, Wolfgang; Kempf, Michael; Scheppach, Wolfgang; Erk, Thomas; Richling, Elke
CS Department of Food Chemistry, University of Wuerzburg, Wuerzburg, Germany
SO Journal of Agricultural and Food Chemistry (2007), 55(26), 10605-10614
CODEN: JAFCAU; ISSN: 0021-8561
PB American Chemical Society
DT Journal
LA English
AB Polyphenols are secondary plant compds. showing anticarcinogenic effects both in vitro and in animal expts. and may thus reduce the risk of colorectal cancer in man. The identification of polyphenol metabolites formed via their passage through the small intestine of healthy ileostomy subjects after apple juice consumption is presented. Identification and quantification of polyphenols and their metabolites were performed using HPLC-DAD as well as HPLC-ESI-MS/MS. Total procyanidin content (TPA) was measured, and addnl. the mean d.p. (DPm) of the procyanidins was determined in the apple juice and ileostomy effluents. As products of polyphenol metabolism, D-(-)-quinic acid and Me esters of caffeic acid and p-coumaric acid are liberated from the corresponding hydroxycinnamic acid esters. 1-Caffeoylquinic acid and 3-caffeoylquinic acid were determined as products of isomerization. Phloretin 2'-O-glucoside (phloridzin) and phloretin 2'-O-xyloglucoside were metabolized into the corresponding aglycons phloretin and phloretin 2'-O-glucuronide and all were found in the ileostomy effluent. Ninety percent of the consumed procyanidins were recovered in the ileostomy effluent and therefore would reach the colon under physiol. circumstances. The DPm was reduced (DPm of apple juice = 5.7) and varied depending on the time point of excretion. The gastrointestinal passage seems to play an important role in the colonic availability of apple polyphenols.

L10 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 2
AN 2006:256838 CAPLUS
DN 145:241079
TI Apple flavonoids inhibit growth of HT29 human colon cancer cells and modulate expression of genes involved in the biotransformation of xenobiotics
AU Veeriah, Selvaraju; Kautenburger, Tanja; Habermann, Nina; Sauer, Julia; Dietrich, Helmut; Will, Frank; Pool-Zobel, Beatrice Louise
CS Department of Nutritional Toxicology, Institute for Nutrition, Friedrich-Schiller-University, Jena, Germany
SO Molecular Carcinogenesis (2006), 45(3), 164-174
CODEN: MOCAE8; ISSN: 0899-1987
PB Wiley-Liss, Inc.
DT Journal
LA English
AB Flavonoids from fruits and vegetables probably reduce risks of diseases

associated with oxidative stress, including cancer. Apples contain significant amts. of flavonoids with antioxidative potential. The objectives of this study were to investigate such compds. for properties associated with reduction of cancer risks. We report herein that apple flavonoids from an apple extract (AE) inhibit colon cancer cell growth and significantly modulate expression of genes related to xenobiotic metabolism HT29 cells were treated with AE at concns. delivering 5-50 μM of one of the major ingredients, phloridzin ("phloridzin-equivalent," Ph.E), to the cell culture medium, with a synthetic flavonoid mixture mimicking the composition of the AE or with 5-100 μM individual flavonoids. HT29 cell growth was inhibited by the complex extract and by the mixture HT29 cells were treated with nontoxic doses of the AE (30 μM, Ph.E) and after 24 h total RNA was isolated to elucidate patterns of gene expression using a human cDNA-microarray (SuperArray) spotted with 96 genes of drug metabolism Treatment with AE resulted in an upregulation of several genes (GSTP1, GSTT2, MGST2, CYP4F3, CHST5, CHST6, and CHST7) and downregulation of EPHX1, in comparison to the medium controls. The enhanced transcriptional activity of GSTP1 and GSTT2 genes was confirmed with real-time qRT-PCR. On the basis of the pattern of differential gene expression found here, we conclude that apple flavonoids modulate toxicol. defense against colon cancer risk factors. In addition to the inhibition of tumor cell proliferation, this could be a mechanism of cancer risk reduction

RE.CNT 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 12 USPATFULL on STN DUPLICATE 3
AN 2005:104652 USPATFULL
TI Herbal composition for treating CD33and chronic myeloid leukemia and a method thereof
IN Bandyopadhyay, Santu, Calcutta, INDIA
Roy, Keshab Chandra, Calcutta, INDIA
Ray, Mitali, Calcutta, INDIA
Banerjee, Goutam, Calcutta, INDIA
Pal, Bikash Chandra, Calcutta, INDIA
Biswas, Tanusree, Calcutta, INDIA
Bhattacharya, Samir, Calcutta, INDIA
PA COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH, NEW DELHI, INDIA (non-U.S. corporation)
PI US 2005089585 A1 20050428
US 7306817 B2 20071211
AI US 2004-960064 A1 20041008 (10)
RLI Division of Ser. No. US 2002-207039, filed on 30 Jul 2002, GRANTED, Pat. No. US 6852344 Continuation-in-part of Ser. No. US 2001-772003, filed on 30 Jan 2001, ABANDONED
PRAI WO 2000-IN118 20001204
US 2002-384163P 20020531 (60)
DT Utility
FS APPLICATION
LREP FITZPATRICK CELLA HARPER & SCINTO, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112, US
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 976
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method of treating CD33+ acute and chronic myeloid leukemia in animals including humans, using fraction nos. 1 and 9 obtained from water:methanol fraction by column chromatography, with ratio of water and methanol ranging between 1:5 to 5:1, wherein said water:methanol fraction is obtained from the polar extract of piper betel by HPLC, with retention time of 3.6 and 24.0

minutes respectively, with said fractions used both individually, and in combination, and a composition comprising the said fraction nos. 1 and 9.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 4
AN 2006:50637 CAPLUS
DN 145:313988
TI Colonic availability of apple polyphenols - a study in ileostomy subjects
AU Kahle, Kathrin; Kraus, Michael; Scheppach, Wolfgang; Richling, Elke
CS Department of Food Chemistry, University of Wuerzburg, Wuerzburg, Germany
SO Molecular Nutrition & Food Research (2005), 49(12), 1143-1150
CODEN: MNFRCV; ISSN: 1613-4125
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English
AB Nutrition is thought to play an essential role in the pathogenesis of inflammatory and malignant gastrointestinal diseases. It is well known that plant ingredients such as polyphenols and flavonoids show anticarcinogenic effects both in vitro and in animal expts., and may thus reduce the risk of colorectal cancer in man. The aim of the study was to determine the amount of polyphenols reaching the colon after oral intake of apple juice. After consumption of a polyphenol-free diet 11 healthy ileostomy volunteers drank 1 L of a polyphenol-rich cloudy apple juice. Ileostomy effluent was collected immediately before and 1, 2, 4, 6, and 8 h after consumption of apple juice. A broad spectrum of polyphenols was identified using HPLC-diode array detection (HPLC-DAD) as well as HPLC-ESI-MS/MS; quantitation was performed with HPLC-DAD. Most of the orally administered apple polyphenols were absorbed from or metabolized in the small intestine. Between 0 and 33% of the oral dose was recovered in the ileostomy bags with a maximum of excretion after 2 h. Phloretin glucuronide as product of polyphenol metabolism was detected in the ileostomy effluent. The present results show that most of the apple juice polyphenols are absorbed in the small intestine. Minor amts. of unmetabolized polyphenols are recovered in the ileostomy effluent, which would reach the colon under physiol. circumstances. These data have to be considered when polyphenols are used in model systems to show preventive effects in colorectal carcinogenesis.
RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:457191 CAPLUS
DN 144:68997
TI Inhibitors of the epidermal growth factor receptor in apple juice extract
AU Kern, Melanie; Tjaden, Zeina; Ngiewih, Yufanyi; Puppel, Nicole; Will, Frank; Dietrich, Helmut; Pahlke, Gudrun; Marko, Doris
CS Department of Chemistry, Division of Food Chemistry and Environmental Toxicology, University of Kaiserslautern, Kaiserslautern, Germany
SO Molecular Nutrition & Food Research (2005), 49(4), 317-328
CODEN: MNFRCV; ISSN: 1613-4125
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English
AB The polyphenol-rich extract of a consumer-relevant apple juice blend was found to potently inhibit the growth of the human colon cancer cell line HT29 in vitro. The epidermal growth factor receptor (EGFR) and its subsequent signaling cascade play an important role in the regulation of cell proliferation in HT29 cells. The protein tyrosine kinase activity of an EGFR preparation was effectively inhibited by the polyphenol-rich apple juice extract Treatment of intact cells with this extract resulted in the

suppression of the subsequent mitogen-activated protein kinase cascade. Amongst the so far identified apple juice constituents, the proanthocyanidins B1 and B2 as well as quercetin-3-glc (isoquercitrin) and quercetin-3-gal (hyperoside) were found to possess substantial EGFR-inhibitory properties. However, as to be expected from the final concentration of these potential EGFR inhibitors in the original polyphenol-rich extract, a synthetic mixture of the apple juice constituents identified and available so far, including both proanthocyanidins and the quercetin glycosides, showed only marginal inhibitory effects on the EGFR. These results permit the assumption that yet unknown constituents contribute substantially to the potent EGFR-inhibitory properties of polyphenol-rich apple juice extract In summary, the polyphenol composition of apple juice possesses promising growth-inhibitory properties, affecting proliferation-associated signaling cascades in colon tumor cells.
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 12 USPATFULL on STN DUPLICATE 5
AN 2004:57084 USPATFULL
TI Herbal based composition for treating acute and chronic myeloid leukemia
IN Bandyopadhyay, Santu, Calcutta, INDIA
Roy, Keshab Chandra, Calcutta, INDIA
Ray, Mitali, Kolkata, INDIA
Bandyopadhyay, Gautam, Kolkata, INDIA
Pal, Bikash Chandra, Kolkata, INDIA
Biswas, Tanusree, Kolkata, INDIA
Bhattacharya, Samir, Kolkata, INDIA
PI US 2004043086 A1 20040304
US 6967034 B2 20051122
AI US 2003-448398 A1 20030530 (10)
PRAI US 2002-384163P 20020531 (60)
DT Utility
FS APPLICATION
LREP FITZPATRICK CELLA HARPER & SCINTO, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 460
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A new herbal-based composition and method for treatment of CD33+ acute and chronic myeloid leukemia by Piper betel leaf extracts, and to provide a process for the isolation of active fractions from leaves or any other plant parts of Piper betel to treat CD3 3+ AML and CML with a simplified method of isolation of active components from all plant parts of Piper betel possessing biological activities relevant to the treatment of CD33+ AML and CML.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 9 OF 12 USPATFULL on STN
AN 2004:69647 USPATFULL
TI Synergistic composition for treating leukemia
IN Bandyopadhyay, Santu, Kolkata, INDIA
Chandra Pal, Bikash, Kolkata, INDIA
Bhattacharya, Samir, Kolkata, INDIA
Roy, Keshab Chandra, Kolkata, INDIA
Bandyopadhyay, Gautam, Kolkata, INDIA
PA Council Of Scientific & Industrial Research, New Delhi, INDIA, 110 001 (non-U.S. corporation)
PI US 2004052874 A1 20040318

AI US 2003-613122 A1 20030707 (10)
PRAI US 2002-393750P 20020708 (60)
DT Utility
FS APPLICATION
LREP FITZPATRICK CELLA HARPER & SCINTO, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 685
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a method of treating acute and chronic myeloid leukemia (AML & CML) and lymphoid leukemia, said method comprising administering a pharmaceutical composition comprising pharmaceutically effective amount of chlorogenic acid (CA) and 3-o-p-Coumaryl quinic acid (PCQ) isolated from any plant parts of Piper betel or any other source, both individually or in a synergistic combination optionally along with pharmaceutically acceptable additives.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 10 OF 12 USPATFULL on STN
AN 2004:7898 USPATFULL
TI Pharmaceutical composition useful for treating chronic myeloid leukemia
IN Bandyopadhyay, Santu, Kolkata, INDIA
Pal, Bikas Chandra, Kolkata, INDIA
Bhattacharyay, Samir, Kolkata, INDIA
Mondal, Swapan, Calcutta, INDIA
Mandal, Chhabinath, Calcutta, INDIA
Konar, Aditya, Calcutta, INDIA
Roy, Keshab Chandra, Calcutta, INDIA
Biswas, Tanusree, Calcutta, INDIA
Bandyopadhyay, Gautam, Calcutta, INDIA
PA COUNCIL OF SCIENTIFIC (non-U.S. corporation)
INDUSTRIAL RESEARCH (non-U.S. corporation)
PI US 2004006138 A1 20040108
AI US 2003-338689 A1 20030109 (10)
PRAI US 2002-393750P 20020708 (60)
DT Utility
FS APPLICATION
LREP FITZPATRICK CELLA HARPER & SCINTO, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 591
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a pharmaceutical composition useful for treating chronic myeloid leukemia where Bcr-Abl kinase is constitutively expressed in animals and humans, said composition comprising an effective amount of analogs of chlorogenic acid such as neochlorogenic acid (5-O-caffeoyl quinic acid), cryptochlorogenic acid (4-O-Caffeoyl quinic acid), 3-O-(3'-methylcaffeoyl) quinic acid and 5-O-(Caffeoyl-4'-methyl) quinic acid and/or its salts such as sodium, potassium and ammonium together with pharmaceutically acceptable additives.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 11 OF 12 USPATFULL on STN DUPLICATE 6
AN 2003:71049 USPATFULL
TI Herbal composition for treating CD33+ acute and chronic myeloid leukemia

and a method thereof
IN Bandyopadhyay, Santu, Calcutta, INDIA
Roy, Keshab Chandra, Calcutta, INDIA
Ray, Mitali, Calcutta, INDIA
Banerjee, Goutam, Calcutta, INDIA
Pal, Bikash Chandra, Calcutta, INDIA
Biswas, Tanusree, Calcutta, INDIA
Bhattacharya, Samir, Calcutta, INDIA
PA COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (non-U.S. corporation)
PI US 2003049334 A1 20030313
US 6852344 B2 20050208
AI US 2002-207039 A1 20020730 (10)
RLI Continuation-in-part of Ser. No. US 2001-772003, filed on 30 Jan 2001, ABANDONED
PRAI WO 2000-IN118 20001204
US 2002-384163P 20020531 (60)
DT Utility
FS APPLICATION
LREP FITZPATRICK CELLA HARPER & SCINTO, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112
CLMN Number of Claims: 46
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 1041
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method of treating CD33+ acute and chronic myeloid leukemia in animals including humans, using fraction nos. 1 and 9 obtained from water:methanol fraction by column chromatography, with ratio of water and methanol ranging between 1:5 to 5:1, wherein said water:methanol fraction is obtained from the polar extract of piper betel by HPLC, with retention time of 3.6 and 24.0 minutes respectively, with said fractions used both individually, and in combination, and a composition comprising the said fraction nos. 1 and 9.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 12 OF 12 USPATFULL on STN
AN 2003:325158 USPATFULL
TI Herbal molecule as potential anti-leukemic drug
IN Bandyopadhyay, Santu, Calcutta, INDIA
Pal, Bikash Chandra, Kolkata, INDIA
Bhattacharya, Samir, Kolkata, INDIA
Roy, Keshab Chandra, Kolkata, INDIA
Bandyopadhyay, Gautam, Kolkata, INDIA
PI US 2003229140 A1 20031211
AI US 2003-338688 A1 20030109 (10)
PRAI WO 2002-IB5565 20021220
US 2002-384163P 20020531 (60)
US 2002-393750P 20020708 (60)
DT Utility
FS APPLICATION
LREP FITZPATRICK CELLA HARPER & SCINTO, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112
CLMN Number of Claims: 49
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 676
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a new use of the compound chlorogenic acid isolated from the piper betel leaf extract or from any other sources for the treatment of acute and chronic myeloid leukemia and

lymphoid leukemia, and the present invention also provides a pharmaceutical composition comprising chloregenic acid along with pharmaceutically acceptable additive for the treatment of acute and chronic myeloid leukemia and lymphoid leukemia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s l3 and tumor
  28 FILES SEARCHED...
L11   15 L3 AND TUMOR

=> s l3 and tumour
L12   0 L3 AND TUMOUR

=> dup rem l11
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGMONOG2, IMSPRODUCT, KOSMET, NUTRACEUT, PCTGEN, PHARMAML, USGENE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L11
L13   9 DUP REM L11 (6 DUPLICATES REMOVED)

=> d l13 bib abs 1-9

L13 ANSWER 1 OF 9 USPATFULL on STN
AN   2007:184711 USPATFULL
TI   Pharmaceutical composition useful for treating chronic myeloid leukemia
IN   Bandyopadhyay, Santu, Kolkata, INDIA
       Pal, Bikas Chandra, Kolkata, INDIA
       Bhattacharyay, Samir, Kolkata, INDIA
       Mondal, Swapan, Kolkata, INDIA
       Mandal, Chhabinath, Kolkata, INDIA
       Konar, Aditya, Kolkata, INDIA
       Roy, Keshab Chandra, Kolkata, INDIA
       Biswas, Tanusree, Kolkata, INDIA
       Bandyopadhyay, Gautam, Kolkata, INDIA
PA   COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH, NEW DELHI, INDIA
       (non-U.S. corporation)
PI   US 2007161704   A1 20070712
AI   US 2006-640401   A1 20061218 (11)
RLI   Continuation of Ser. No. US 2005-174545, filed on 6 Jul 2005, ABANDONED
       Continuation-in-part of Ser. No. US 2003-338689, filed on 9 Jan 2003, ABANDONED
PRAI   US 2002-393750P   20020708 (60)
DT   Utility
FS   APPLICATION
LREP   FITZPATRICK CELLA HARPER & SCINTO, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112, US
CLMN   Number of Claims: 24
ECL   Exemplary Claim: 1-44
DRWN   10 Drawing Page(s)
LN.CNT 817
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB   This invention relates to a pharmaceutical composition useful for treating chronic myeloid leukemia where Bcr-Abl kinase is constitutively expressed in animals and humans, and a treatment of chronic myeloid leukemia (CML) by a composition comprising an effective amount of analogs and/or salts of chlorogenic acid. The analogs are preferably sodium chlorogenate (Na-Chl) or potassium or ammonium salts, which were prepared from Chlorogenic acid or its analogs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:334525 CAPLUS
DN 146:513979
TI Apple Polyphenols and Products Formed in the Gut Differently Inhibit Survival of Human Cell Lines Derived from Colon Adenoma (LT97) and Carcinoma (HT29)
AU Veeriah, Selvaraju; Hofmann, Thomas; Glei, Michael; Dietrich, Helmut; Will, Frank; Schreier, Peter; Knaup, Bastian; Pool-Zobel, Beatrice Louise
CS Department of Nutritional Toxicology, Institute for Nutrition, Friedrich-Schiller-University, Jena, D-07743, Germany
SO Journal of Agricultural and Food Chemistry (2007), 55(8), 2892-2900
CODEN: JAFCAU; ISSN: 0021-8561
PB American Chemical Society
DT Journal
LA English
AB Colorectal tumor risks could be reduced by polyphenol-rich diets that inhibit cell growth. Here, apple polyphenols were studied for effects on the survival of colon adenoma (LT97) and carcinoma-derived (HT29) cell lines. Three apple exts. (AEs) from harvest years 2002-2004 were isolated (AE02, AE03, and AE04) and fermented in vitro with human fecal flora. Exts. and fermentation products were analyzed for polyphenols with HPLC. The cells were treated with AEs (0-850 μg/mL) or fermented AEs (F-AEs, 0-9%), and survival was measured by DNA staining. All AEs contained high amts. of polyphenols (311-534 mg/g) and reduced cell survival (in LT97 > HT29). AE03 was most potent, possibly because it contained more quercetin compds. Fermentation of AEs resulted in an increase of short chain fatty acids, and polyphenols were degraded. The F-AEs were .apprx.3-fold less bioactive than the corresponding AEs, pointing to a loss of chemoprotective properties through fermentation
RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 1
AN 2006:256838 CAPLUS
DN 145:241079
TI Apple flavonoids inhibit growth of HT29 human colon cancer cells and modulate expression of genes involved in the biotransformation of xenobiotics
AU Veeriah, Selvaraju; Kautenburger, Tanja; Habermann, Nina; Sauer, Julia; Dietrich, Helmut; Will, Frank; Pool-Zobel, Beatrice Louise
CS Department of Nutritional Toxicology, Institute for Nutrition, Friedrich-Schiller-University, Jena, Germany
SO Molecular Carcinogenesis (2006), 45(3), 164-174
CODEN: MOCAE8; ISSN: 0899-1987
PB Wiley-Liss, Inc.
DT Journal
LA English
AB Flavonoids from fruits and vegetables probably reduce risks of diseases associated with oxidative stress, including cancer. Apples contain significant amts. of flavonoids with antioxidative potential. The objectives of this study were to investigate such compds. for properties associated with reduction of cancer risks. We report herein that apple flavonoids from an apple extract (AE) inhibit colon cancer cell growth and significantly modulate expression of genes related to xenobiotic metabolism HT29 cells were treated with AE at concns. delivering 5-50 μM of one of the major ingredients, phloridzin ("phloridzin-equivalent," Ph.E), to the cell culture medium, with a synthetic flavonoid mixture mimicking the composition of the AE or with 5-100 μM individual flavonoids. HT29 cell growth was inhibited by the complex extract and by the mixture HT29 cells were treated

with nontoxic doses of the AE (30 μM, Ph.E) and after 24 h total RNA was isolated to elucidate patterns of gene expression using a human cDNA-microarray (SuperArray) spotted with 96 genes of drug metabolism Treatment with AE resulted in an upregulation of several genes (GSTP1, GSTT2, MGST2, CYP4F3, CHST5, CHST6, and CHST7) and downregulation of EPHX1, in comparison to the medium controls. The enhanced transcriptional activity of GSTP1 and GSTT2 genes was confirmed with real-time qRT-PCR. On the basis of the pattern of differential gene expression found here, we conclude that apple flavonoids modulate toxicol. defense against colon cancer risk factors. In addition to the inhibition of tumor cell proliferation, this could be a mechanism of cancer risk reduction

RE.CNT 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:457191 CAPLUS
DN 144:68997
TI Inhibitors of the epidermal growth factor receptor in apple juice extract
AU Kern, Melanie; Tjaden, Zeina; Ngiewih, Yufanyi; Puppel, Nicole; Will, Frank; Dietrich, Helmut; Pahlke, Gudrun; Marko, Doris
CS Department of Chemistry, Division of Food Chemistry and Environmental Toxicology, University of Kaiserslautern, Kaiserslautern, Germany
SO Molecular Nutrition & Food Research (2005), 49(4), 317-328
CODEN: MNFRCV; ISSN: 1613-4125
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English
AB The polyphenol-rich extract of a consumer-relevant apple juice blend was found to potently inhibit the growth of the human colon cancer cell line HT29 in vitro. The epidermal growth factor receptor (EGFR) and its subsequent signaling cascade play an important role in the regulation of cell proliferation in HT29 cells. The protein tyrosine kinase activity of an EGFR preparation was effectively inhibited by the polyphenol-rich apple juice extract Treatment of intact cells with this extract resulted in the suppression of the subsequent mitogen-activated protein kinase cascade. Amongst the so far identified apple juice constituents, the proanthocyanidins B1 and B2 as well as quercetin-3-glc (isoquercitrin) and quercetin-3-gal (hyperoside) were found to possess substantial EGFR-inhibitory properties. However, as to be expected from the final concentration of these potential EGFR inhibitors in the original polyphenol-rich
extract, a synthetic mixture of the apple juice constituents identified and available so far, including both proanthocyanidins and the quercetin glycosides, showed only marginal inhibitory effects on the EGFR. These results permit the assumption that yet unknown constituents contribute substantially to the potent EGFR-inhibitory properties of polyphenol-rich apple juice extract In summary, the polyphenol composition of apple juice possesses promising growth-inhibitory properties, affecting proliferation-associated signaling cascades in colon tumor cells.

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 2
AN 2004:780424 CAPLUS
DN 141:266084
TI Extracorporeal blood treatment system using ultraviolet light and filters
IN Mallett, Scott R.; Davidner, Alan A.; Walker, Kimberly A.
PA USA
SO U.S. Pat. Appl. Publ., 29 pp.
CODEN: USXXCO
DT Patent
LA English

FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040186412	A1	20040923	US 2003-391453	20030317
	WO 2004082737	A2	20040930	WO 2004-US7590	20040312
	WO 2004082737	A3	20050512		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20060210424	A1	20060921	US 2006-417717	20060503
PRAI	US 2003-390558	A	20030317		
	US 2003-390565	A	20030317		
	US 2003-390572	A	20030317		
	US 2003-391443	A	20030317		
	US 2003-391444	A	20030317		
	US 2003-391445	A	20030317		
	US 2003-391453	A	20030317		
	US 2003-391454	A	20030317		
	US 2003-391455	A	20030317		

AB A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of blood-borne microorganisms, a hemoconcentrator/filtration unit to remove approx. 50-75% of target mols. from the patient blood and a filter unit to remove target mols. from patient blood from the sieved plasma filtrate. Target mols. are produced by microorganisms, as well as by the patient's cells. These mols. include endotoxins from Gram neg. bacteria, exotoxins from Gram neg. and Gram pos. bacteria, as well as RAP protein mediator from Staphylococcus aureus , and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin. Over one thousand in vitro expts. were conducted using several embodiments of the present invention. Factors investigated included appropriate UV transparent material, hematocrit of blood for optimal UV absorption, ideal blood flow path for adequate UV exposure, ideal UV dosage, ideal pore size of hemofilters, ideal surface area of hemofilters, ideal blood model, development of porcine cytokine assays, various circuit coatings and optimal flow rates.

L13 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 3
AN 2004:780423 CAPLUS
DN 141:266083
TI Irradiation and filter device for treatment of blood
IN Mallett, Scott R.; Davidner, Alan A.; Walker, Kimberly A.
PA Hemavation, USA
SO U.S. Pat. Appl. Publ., 29 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040186411	A1	20040923	US 2003-390572	20030317
	US 7229427	B2	20070612		
	WO 2004082737	A2	20040930	WO 2004-US7590	20040312
	WO 2004082737	A3	20050512		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-390558 A 20030317
US 2003-390565 A 20030317
US 2003-390572 A 20030317
US 2003-391443 A 20030317
US 2003-391444 A 20030317
US 2003-391445 A 20030317
US 2003-391453 A 20030317
US 2003-391454 A 20030317
US 2003-391455 A 20030317

AB A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of blood-borne microorganisms, a hemoconcentrator/filtration unit to remove approx. 50-75% of target mols. from the patient blood and a filter unit to remove target mols. from patient blood from the sieved plasma filtrate. Target mols. are produced by microorganisms, as well as by the patient's cells. These mols. include endotoxins from Gram neg. bacteria, exotoxins from Gram neg. and Gram pos. bacteria, as well as RAP protein mediator from Staphylococcus aureus , and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin. Over one thousand in vitro expts. were conducted using several embodiments of the present invention. Factors investigated included appropriate UV transparent material, hematocrit of blood for optimal UV absorption, ideal blood flow path for adequate UV exposure, ideal UV dosage, ideal pore size of hemofilters, ideal surface area of hemofilters, ideal blood model, development of porcine cytokine assays, various circuit coatings and optimal flow rates.

RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 7 OF 9 USPATFULL on STN
AN 2004:69647 USPATFULL
TI Synergistic composition for treating leukemia
IN Bandyopadhyay, Santu, Kolkata, INDIA
Chandra Pal, Bikash, Kolkata, INDIA
Bhattacharya, Samir, Kolkata, INDIA
Roy, Keshab Chandra, Kolkata, INDIA
Bandyopadhyay, Gautam, Kolkata, INDIA
PA Council Of Scientific & Industrial Research, New Delhi, INDIA, 110 001 (non-U.S. corporation)
PI US 2004052874 A1 20040318
AI US 2003-613122 A1 20030707 (10)
PRAI US 2002-393750P 20020708 (60)
DT Utility
FS APPLICATION
LREP FITZPATRICK CELLA HARPER & SCINTO, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 685
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method of treating acute and chronic myeloid leukemia (AML & CML) and lymphoid leukemia, said method

comprising administering a pharmaceutical composition comprising pharmaceutically effective amount of chlorogenic acid (CA) and 3-o-p-Coumaryl quinic acid (PCQ) isolated from any plant parts of Piper betel or any other source, both individually or in a synergistic combination optionally along with pharmaceutically acceptable additives.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 8 OF 9 USPATFULL on STN
AN 2004:7898 USPATFULL
TI Pharmaceutical composition useful for treating chronic myeloid leukemia
IN Bandyopadhyay, Santu, Kolkata, INDIA
Pal, Bikas Chandra, Kolkata, INDIA
Bhattacharyay, Samir, Kolkata, INDIA
Mondal, Swapan, Calcutta, INDIA
Mandal, Chhabinath, Calcutta, INDIA
Konar, Aditya, Calcutta, INDIA
Roy, Keshab Chandra, Calcutta, INDIA
Biswas, Tanusree, Calcutta, INDIA
Bandyopadhyay, Gautam, Calcutta, INDIA
PA COUNCIL OF SCIENTIFIC (non-U.S. corporation)
INDUSTRIAL RESEARCH (non-U.S. corporation)
PI US 2004006138 A1 20040108
AI US 2003-338689 A1 20030109 (10)
PRAI US 2002-393750P 20020708 (60)
DT Utility
FS APPLICATION
LREP FITZPATRICK CELLA HARPER & SCINTO, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 591
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a pharmaceutical composition useful for treating chronic myeloid leukemia where Bcr-Abl kinase is constitutively expressed in animals and humans, said composition comprising an effective amount of analogs of chlorogenic acid such as neochlorogenic acid (5-O-caffeoyl quinic acid), cryptochlorogenic acid (4-O-Caffeoyl quinic acid), 3-O-(3'-methylcaffeoyl) quinic acid and 5-O-(Caffeoyl-4'-methyl) quinic acid and/or its salts such as sodium, potassium and ammonium together with pharmaceutically acceptable additives.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 9 OF 9 USPATFULL on STN
AN 2003:325158 USPATFULL
TI Herbal molecule as potential anti-leukemic drug
IN Bandyopadhyay, Santu, Calcutta, INDIA
Pal, Bikash Chandra, Kolkata, INDIA
Bhattacharya, Samir, Kolkata, INDIA
Roy, Keshab Chandra, Kolkata, INDIA
Bandyopadhyay, Gautam, Kolkata, INDIA
PI US 2003229140 A1 20031211
AI US 2003-338688 A1 20030109 (10)
PRAI WO 2002-IB5565 20021220
US 2002-384163P 20020531 (60)
US 2002-393750P 20020708 (60)
DT Utility
FS APPLICATION
LREP FITZPATRICK CELLA HARPER & SCINTO, 30 ROCKEFELLER PLAZA, NEW YORK, NY,

10112
CLMN Number of Claims: 49
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 676
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a new use of the compound chlorogenic acid isolated from the piper betel leaf extract or from any other sources for the treatment of acute and chronic myeloid leukemia and lymphoid leukemia, and the present invention also provides a pharmaceutical composition comprising chloregenic acid along with pharmaceutically acceptable additive for the treatment of acute and chronic myeloid leukemia and lymphoid leukemia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	159.45	181.41

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-11.20	-11.20

STN INTERNATIONAL LOGOFF AT 16:56:39 ON 10 APR 2008